Skip to content
DataLookout
Menu

NCT06618963

Effect of Omalizumab in the Skin of Food Allergy Patients

StatusRecruiting
PhasePhase 4
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 27 words
    • Primary completion date changed from estimate of Sep 2026 to Nov 3, 2026
    • Secondary endpoints: details revised at 3 of 5 entries
    • Study description expanded, about 5 words
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Lipidomic analysis
Timeframe: 5 months
Metabolomic analysis
Timeframe: 5 months
Proteomic analysis
Timeframe: 5 months
Cytokine analysis
Timeframe: 5 months
Measurement of Transepidermal Water Loss
Timeframe: 5 months

Secondary (5)

Measurement of Transepidermal Water Loss in non Food-Allergic Subjects
Lipidomic analysis in non Food-Allergic participants
Metabolomic analysis in non Food-Allergic Participants
Proteomic analysis in non Food-Allergic Participants
Cytokine analysis

Arms and interventions

Participants with Food AllergyActive comparator

This group will receive 4 months of Omalizumab treatment, and undergo regular skin barrier assessments.

Participants without Food AllergyNo intervention

This group will undergo skin barrier assessment.

Drugs: Omalizumab Injection

Sites

1 site in 1 country

  • National Jewish HealthDenver, Colorado, United States